117 related articles for article (PubMed ID: 33750906)
1. Correlative analysis between two commercially available post-prostatectomy genomic tests.
Shahait M; Alshalalfa M; Nguyen PL; Al-Fahmawi A; Dobbs RW; Lal P; Lee DI
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):575-577. PubMed ID: 33750906
[TBL] [Abstract][Full Text] [Related]
2. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy.
Shangguan X; Qian H; Jiang Z; Xin Z; Pan J; Dong B; Xue W
J Cancer Res Clin Oncol; 2020 Mar; 146(3):687-694. PubMed ID: 31745702
[TBL] [Abstract][Full Text] [Related]
4. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
5. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
[TBL] [Abstract][Full Text] [Related]
7. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.
Léon P; Cancel-Tassin G; Drouin S; Audouin M; Varinot J; Comperat E; Cathelineau X; Rozet F; Vaessens C; Stone S; Reid J; Sangale Z; Korman P; Rouprêt M; Fromond-Hankard G; Cussenot O
World J Urol; 2018 Sep; 36(9):1495-1500. PubMed ID: 29679140
[TBL] [Abstract][Full Text] [Related]
9. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
10. The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status.
Magi-Galluzzi C; Isharwal S; Falzarano SM; Tsiatis A; Dee A; Maddala T; Knezevic D; Febbo PG; Lawrence J; Klein EA
Urology; 2018 Nov; 121():132-138. PubMed ID: 30142405
[TBL] [Abstract][Full Text] [Related]
11. Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.
Koch MO; Cho JS; Kaimakliotis HZ; Cheng L; Sangale Z; Brawer M; Welbourn W; Reid J; Stone S
Cancer Biomark; 2016 Jun; 17(1):83-8. PubMed ID: 27314296
[TBL] [Abstract][Full Text] [Related]
12. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
13. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
14. Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting.
Glass AG; Leo MC; Haddad Z; Yousefi K; du Plessis M; Chen C; Choeurng V; Abdollah F; Robbins B; Ra S; Richert-Boe KE; Buerki C; Pearson K; Davicioni E; Weinmann S
J Urol; 2016 Jun; 195(6):1748-53. PubMed ID: 26626216
[TBL] [Abstract][Full Text] [Related]
15. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.
Ross AE; Feng FY; Ghadessi M; Erho N; Crisan A; Buerki C; Sundi D; Mitra AP; Vergara IA; Thompson DJ; Triche TJ; Davicioni E; Bergstralh EJ; Jenkins RB; Karnes RJ; Schaeffer EM
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):64-9. PubMed ID: 24145624
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
Freedland SJ; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Gutin A; Sangale Z; Lanchbury JS; Salama JK; Stone S
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):848-53. PubMed ID: 23755923
[TBL] [Abstract][Full Text] [Related]
17. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy.
Marascio J; Spratt DE; Zhang J; Trabulsi EJ; Le T; Sedzorme WS; Beeler WH; Davicioni E; Dabbas B; Lin DW; Gore JL; Bloom M; Mann M; Mark JR; Calvaresi A; Godwin JL; McCue P; Hurwitz MD; Kelly WK; Lallas CD; Knudsen KE; Gomella LG; Dicker AP; Den RB
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):295-302. PubMed ID: 31719663
[TBL] [Abstract][Full Text] [Related]
18.
Faisal FA; Murali S; Kaur H; Vidotto T; Guedes LB; Salles DC; Kothari V; Tosoian JJ; Han S; Hovelson DH; Hu K; Spratt DE; Baras AS; Tomlins SA; Schaeffer EM; Lotan TL
Clin Cancer Res; 2020 Jun; 26(11):2595-2602. PubMed ID: 31969336
[TBL] [Abstract][Full Text] [Related]
19. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
20. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.
Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A
BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
